🔺 What to do when markets are at an all-time high? Find smart bargains, like these.See Undervalued Stocks

TD Cowen maintains Buy on Lantheus, price target at $110

EditorLina Guerrero
Published 11/11/2024, 02:59 PM
LNTH
-

On Monday, TD Cowen reaffirmed its confidence in Lantheus Holdings (NASDAQ:LNTH), maintaining a Buy rating and a price target of $110.00. The endorsement comes after a recent update from the Centers for Medicare & Medicaid Services (CMS) regarding payment calculations for Pylarify, a product offered by Lantheus.

The CMS update, released over the weekend, outlined that the Calendar Year (CY) 2025 payment rate for Pylarify will be set at the Medicare Unadjusted Composite Rate (MUC) of $337/mCi. This rate is notably lower than the current payment rates for the agent.

Despite the reduction in the payment rate for Pylarify, the impact on Lantheus is expected to be minimal. The company is actively working on transitioning to the Average Sales Price (ASP) model as swiftly as possible, a move which could mitigate the effects of the lower CMS payment rates.

Lantheus Holdings specializes in the development, manufacture, and commercialization of innovative diagnostic imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Pylarify is one such agent used in PET imaging to identify suspected prostate cancer recurrence.

The affirmation of the Buy rating and price target by TD Cowen signals their belief in the ongoing value and potential of Lantheus Holdings despite the recent CMS payment update. Lantheus has not publicly responded to the CMS update or the maintained rating and price target by TD Cowen.

In other recent news, Lantheus Holdings has reported a strong financial performance in its third quarter of 2024, with consolidated net revenue reaching $378.7 million, an 18.4% increase from the same period the previous year. The company's lead product, PYLARIFY, contributed significantly to this growth, with sales hitting approximately $260 million, a 20% year-over-year increase. Lantheus also reported growth in DEFINITY sales, which totaled $77 million. Leerink Partners adjusted their financial outlook for the company, reducing their price target for Lantheus to $122.00 from the previous $127.00 but maintained an Outperform rating on the stock. The firm’s decision follows Lantheus' recent financial results and updated full-year 2024 revenue guidance to a range of $1.51 billion to $1.52 billion.

The company also adjusted its forecast for fully-diluted earnings per share (EPS) for the fiscal year 2024 to between $6.65 and $6.70. Despite the adjustments, Leerink Partners remains optimistic about Lantheus' future, highlighting the company's strong position in the Prostate-Specific Membrane Antigen (PSMA) PET imaging space and an expanding pipeline that has not yet been fully recognized by the market.

InvestingPro Insights

Despite the recent CMS payment update for Pylarify, Lantheus Holdings (NASDAQ:LNTH) continues to demonstrate strong financial performance. According to InvestingPro data, the company has shown impressive revenue growth of 24.15% over the last twelve months as of Q3 2024, with revenues reaching $1.5 billion. This growth is complemented by a healthy gross profit margin of 64.38% and an operating income margin of 41.13%, indicating efficient operations.

InvestingPro Tips highlight that Lantheus has been profitable over the last twelve months and analysts predict continued profitability this year. This aligns with TD Cowen's maintained Buy rating and supports the company's ability to navigate challenges such as the CMS payment rate adjustment.

However, investors should note that the stock has experienced a significant 24.21% decline over the past week, possibly reflecting market reaction to the CMS update. Despite this short-term volatility, Lantheus has demonstrated a strong return over the last five years, suggesting long-term value potential.

For those interested in a deeper analysis, InvestingPro offers 11 additional tips for Lantheus Holdings, providing a more comprehensive view of the company's prospects and challenges.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.